FDA Approves VYEPTI — Lundbeck Pharmaceuticals LLC

The FDA approved Lundbeck’s intravenous CGRP inhibitor VYEPTI for the prevention of episodic migraine, positioning the company to capitalize on the lucrative and rapidly growing migraine therapeutics market. This clearance expands the competitive landscape by offering patients a distinct alternative to daily oral prophylactic medications.